期刊文献+

RP-HPLC测定人尿液中甲磺酸帕珠沙星的浓度 被引量:1

Determination of pazufloxacin mesilate in human urine by RP-HPLC
暂未订购
导出
摘要 目的 建立测定甲磺酸帕珠沙星的尿药浓度的方法,计算累积尿药排泄率.方法 采用反相高效液相色谱(RP-HPLC)法,色谱柱为C18柱(4.6 mm×150 mm,5μm),柱温35℃;流动相:乙腈-甲醇-水(6∶12∶82,含0.01%磷酸和0.01%三乙胺);流速:1.10 ml/min;检测波长:245 nm.结果 甲磺酸帕珠沙星最低定量浓度为13.6 μg/ml;尿药标准曲线线性范围为13.6~2720 μg/ml (r=0.9997),方法回收率>90%;日内、日间精密度(RSD)<10.0%.30名健康志愿者进行单剂量静脉注射低、中、高三种剂量的注射用甲磺酸帕珠沙星后,帕珠沙星在24 h内尿液中的累积尿药排泄率分别为(92.63±5.04)%、(91.21±2.09)%、(90.22±3.53)%.结论 该方法快速、简便、准确度高,专属性好,无杂质干扰,适用于帕珠沙星体内药物浓度的测定及药代动力学研究. Objective To establish a method to determine the urine concentration of pazufloxacin mesilate and calcu- late cumulative urinary excretion rate.Methods Reversed phase high performance liquid chromatography (RP-HPLC) was established,the column was Cts (4.6 mm150 mm,5 μm),column temperature was 35C,with acetonitrile-methanol-water (0.01% H3PO4 and 0.01% triethyamin) of 6:12:82 as the mobile phase.The flow rate was 1.10 ml/min.The detection wavelength was 245 nm.Results The calibration curve was linear in the range of 13.6 to 2720 pg/ml (r=0.9997) for pazu- floxacin.The methodology recoveries was higher than 90% for the anahytes.The RSD value of within-day and between- day was less than 10.0%.After being given an iv administration of single dose including low,medium and high of pazu- floxacin mesilate,the accumulative urine exeretion rate of 30 volunteers during 24 h was (92.63+_5.04)%,(91.21_+2.09)%, (90.22+3.53)% respectively.Conclusion The method is accurate,sensitive,specific and reliable for pazufloxacin,and the impurities do not interrupt.It may be applied to study drug concentration and pharmacokinetic.
出处 《中国当代医药》 2014年第8期9-11,共3页 China Modern Medicine
基金 中南大学湘雅医院校级横向课题
关键词 甲磺酸帕珠沙星 反相高效液相色谱法 尿药浓度 Pazufloxacin mesilate Reversed phase high performance liquid chromatography Urine concentration
  • 相关文献

参考文献16

  • 1Misuyama J, Miyazaki S, Ishii Y,et al.Antibacterial activity of a new injectable quinolone pazufloxacin in vitro and in vivo[J].Jpn J Chemother, 1999,47(Suppl 1) : 1-15.
  • 2Mitsuyama J,Takahata M, Yamashiro Y,et al.Antibacterial activity of a new injectable quinolone,pazufloxacin mesilate (PZFX mesilate),in vitro and in vivo[J].Jpn J Chemother, 1999,47(Suppl 1 ) :37-64.
  • 3Nishino T,Ikeda Y,Otsuki m,et al.ln vitro and in vivo an- tibacterial activity of pazufloxacin mesilate ,a new parenter- al fluoroquinolone[J].Jpn J Chemother, 1999,47 (Suppl 1 ) :25-36.
  • 4Mikamo H,Sato Y,Hayasaki Y,et al.ln vitro acrtivities of pazufloxacin,an injectable new quinolone,against bacteria causing infections in obstertrie and gynecological patients [J].Jpn J Chemother, 1999,47(Suppl 1 ) : 16-38.
  • 5Lee J,Seong SJ,Lim MS,et al.Single-dose pharmacoki- netics and dose proportionality of intravenous pazufloxacin mesilate in healthy Korean volunteers[J].Expert Opin Drug Metab Toxicol, 2012,8 (8) : 921-928.
  • 6Phapale PB,Lee HW, Kim SD,et al.Analysis of pazufloxacin mesilate in human plasma and urine by LC with fluores- cence and UV detection,and its application to pharma- cokinetic study [J].Chromatographia, 2010,71 (1-2) : 101 - 106.
  • 7王进,肖永红,张薇,吕媛,康子胜,张明,刘燕,夏亚红,李天云.多剂量甲磺酸帕珠沙星氯化钠注射液在健康人体的药代动力学[J].中国临床药理学杂志,2007,23(1):24-27. 被引量:4
  • 8李德天,边晓慧,王鹏.国产甲磺酸帕珠沙星注射剂在健康人体的药代动力学[J].中国临床药理学杂志,2005,21(5):351-354. 被引量:2
  • 9王宪刚,苗佳,梁德荣,余勤,梁茂植,张淑华.甲磺酸帕珠沙星注射液临床药代动力学/药效学研究[J].四川大学学报(医学版),2009,40(4):689-693. 被引量:8
  • 10张华峰,张福成,王健康,戴博.甲磺酸帕珠沙星注射液在人体内的药代动力学研究[J].解放军药学学报,2009,25(5):417-420. 被引量:3

二级参考文献45

共引文献25

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部